iBio, Inc.
IBIO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2 |
| % Growth | 77.8% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $4 |
| Gross Profit | $0 | $0 | $0 | -$2 |
| % Margin | 100% | 100% | – | -101.2% |
| R&D Expenses | $8 | $5 | $10 | $10 |
| G&A Expenses | $11 | $12 | $19 | $0 |
| SG&A Expenses | $11 | $12 | $19 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $17 | $29 | $28 |
| Operating Income | -$19 | -$17 | -$29 | -$30 |
| % Margin | -4,650.5% | -7,392.9% | – | -1,576.3% |
| Other Income/Exp. Net | $0 | $1 | $0 | $0 |
| Pre-Tax Income | -$18 | -$15 | -$29 | -$30 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$25 | -$65 | -$50 |
| % Margin | -4,594.3% | -11,069.8% | – | -2,674.7% |
| EPS | -1.75 | -6.5 | -23.94 | -58.49 |
| % Growth | 73.1% | 72.8% | 59.1% | – |
| EPS Diluted | -1.75 | -6.5 | -23.94 | -58.49 |
| Weighted Avg Shares Out | 10 | 4 | 1 | 1 |
| Weighted Avg Shares Out Dil | 10 | 4 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $4 |
| EBITDA | -$17 | -$14 | -$28 | -$26 |
| % Margin | -4,259.8% | -6,231.6% | – | -1,365.3% |